European Life Sciences Start-Ups Maintain Early Investor Allure
Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.
You may also be interested in...
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.